Adverse Effects

Brain Cancer

HER2-Positive Breast Cancer

Triple-Negative Breast Cancer

Breast Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Liver Cancer

Pancreatic Cancer

Gastrointestinal Cancer

Bladder Cancer

Kidney Cancer

Prostate Cancer

Genitourinary Cancers

Cervical Cancer

Endometrial Cancer

Ovarian Cancer

Gynecologic Cancers

Head & Neck Cancer

Multiple Myeloma

Myelodysplastic Syndromes

Myeloproliferative Neoplasms

Hematologic Oncology

Vaccines

Infection

Leukemia

Non-Small Cell Lung Cancer (NSCLC)

Small Cell Lung Cancer (SCLC)

Lung Cancer

Lymphoma

Neuroendocrine Tumors

Oncology

Pediatric Cancers

Radiation Oncology

Sarcoma

Screening

Skin Cancer & Melanoma

Surgery

Thyroid Cancer

News

Global Bulletin

All News

FDA Approval Alert

Women in Oncology

Media

Around the Practice

Between the Lines

Face Off

From All Angles

Meeting of the Minds

OncView

Podcasts

Training Academy

Treatment Algorithms with the Oncology Brothers

Videos

Conferences

Publications

All Journals

Editorial Board

For Authors

Year in Review

Events

Frontline Forum

Satellite Sessions

CME/CE

Resources

Awareness Month

Nurse Practitioners/Physician's Assistants

Partners

Career Center

Subscribe

CancerNetwork is home to the journal Oncology & provides insights on the screening, early detection, diagnosis, treatment and prevention of cancers.

About

Advertise

CureToday.com

OncLive.com

OncNursingNews.com

TargetedOnc.com

Editorial

Contact

Terms and Conditions

Privacy

Do Not Sell My Personal Information

CancerNetwork - Oncology News and Clinical Expertise

Facebook

LinkedIn

Youtube

Spotlight

Clinical

Genitourinary Cancer

Gynecologic Cancer

Hematology

Skin Cancer

1rem

View

Analyses on the Impact of Tumor Burden at Progression and Changes in IMDC Risk Scores in the CLEAR Trial Prognostic Insights in Advanced RCC With Lenvatinib Plus Pembrolizumab

Video Series

Experts discuss risk score stability and post lenvatinib plus pembrolizumab treatment selection in renal cell carcinoma.

Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC

Experts discuss the analyses on the impact of tumor burden at progression and changes in IMDC risk scores in the CLEAR trial, providing prognostic insights in advanced RCC with lenvatinib plus pembrolizumab.

Experts discuss insights from the CLEAR trial on lenvatinib plus pembrolizumab, focusing on depth of response and clinical outcomes in advanced renal cell carcinoma.

CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC

Experts discuss the impact of tumor burden on postprogression survival, exploring strategies to optimize responses in renal cell carcinoma.

Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC

Experts discuss optimizing renal cell carcinoma treatment strategies across the care continuum, from initial response to long-term outcomes.

From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum

Experts discuss the clinical implications from CLEAR post hoc analyses, focusing on IMDC risk assessments and sequencing strategies.

From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses

Experts share clinical pearls on synthesizing risk assessment and response patterns in the management of advanced renal cell carcinoma.

Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management

Experts discuss their approaches to first-line renal cell carcinoma treatment selection, comparing immunotherapy (IO)-IO vs IO-tyrosine kinase inhibitor strategies.

IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection

Experts discuss the KEYMAKER-U03 trial, highlighting lenvatinib plus belzutifan as a promising option in advanced renal cell carcinoma and new directions emerging from the 2025 American Society of Clinical Oncology Genitourinary Cancers Symposium.

KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025

Between The Lines

 is an engaging 30- to 45-minute open discussion showcasing insightful and impactful perspectives from academic and community oncologists on published, peer-reviewed content.

Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC

EP: 1.CLEAR Trial Insights on Lenvatinib Plus Pembrolizumab: Depth of Response and Clinical Outcomes in Advanced RCC

EP: 2.Tumor Burden Impact on Postprogression Survival: Optimizing Strategies for Maximum Response in RCC

EP: 3.From Initial Response to Long-Term Outcomes: Optimizing RCC Treatment Strategies Across the Care Continuum

EP: 4.From IMDC Risk Assessments to Sequencing Strategies: Clinical Implications From CLEAR Post Hoc Analyses

EP: 5.Risk Score Stability and Post Lenvatinib Plus Pembrolizumab Treatment Selection in RCC

EP: 6.Clinical Pearls: Synthesizing Risk Assessment and Response Patterns in Advanced RCC Management

EP: 7.IO-IO vs IO-TKI: Expert Approaches to First-Line RCC Treatment Selection

EP: 8.KEYMAKER-U03: Lenvatinib Plus Belzutifan Emerges as a Promising Option in Advanced RCC and New Directions From ASCO GU 2025